TIGLUTIK, Drug Insight and Market Forecast - 2032

“TIGLUTIK, Drug Insight and Market Forecast - 2032” report provides comprehensive insights about TIGLUTIK for Amyotrophic Lateral Sclerosis in the 7MM. A detailed picture of the TIGLUTIK for Amyotrophic Lateral Sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019-2032 is provided in this report along with a detailed description of the TIGLUTIK for Amyotrophic Lateral Sclerosis. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TIGLUTIK market forecast, analysis for Amyotrophic Lateral Sclerosis in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about emerging therapies in Amyotrophic Lateral Sclerosis.

Drug Summary

TIGLUTIK (Riluzole) oral suspension is indicated for the treatment of Amyotrophic Lateral Sclerosis. TIGLUTIK is the first and only easy-to-swallow thickened Riluzole liquid for Amyotrophic Lateral Sclerosis and is administered twice daily via an oral syringe. This candidate is designed to tackle the issues of disease-related dysphagia in Amyotrophic Lateral Sclerosis. In clinical studies, the most common side effects of TIGLUTIK were oral hypoesthesia, asthenia, nausea, decreased lung function, hypertension, and abdominal pain. These are not all of the possible side effects that a patient may experience with TIGLUTIK.

While Riluzole's mechanism of action is not fully understood, in clinical studies it has been shown repeatedly to modulate glutamate neurotransmission by inhibiting both glutamate release and postsynaptic glutamate receptor signaling. It is ITF Pharma's first commercially available product in the United States.

The recommended dosage for TIGLUTIK is 50 mg (10 mL) taken orally or via Percutaneous Endoscopic Gastrostomy tubes (PEG-tubes) twice daily, every 12 hours. TIGLUTIK should be taken at least 1 hour before or 2 hours after a meal.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the TIGLUTIK description, mechanism of action, dosage and administration, research and development activities in Amyotrophic Lateral Sclerosis.
• Elaborated details on TIGLUTIK regulatory milestones and other development activities have been provided in this report.
• The report also highlights the TIGLUTIK research and development activity in Amyotrophic Lateral Sclerosis details across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around TIGLUTIK.
• The report contains forecasted sales of TIGLUTIK for Amyotrophic lateral sclerosis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for Amyotrophic Lateral Sclerosis.
• The report also features the SWOT analysis with analyst views for TIGLUTIK in Amyotrophic Lateral Sclerosis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by a team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

TIGLUTIK Analytical Perspective

In-depth TIGLUTIK Market Assessment

This report provides a detailed market assessment of TIGLUTIK in Amyotrophic lateral sclerosis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

TIGLUTIK Clinical Assessment

The report provides the clinical trials information of TIGLUTIK in Amyotrophic Lateral Sclerosis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for Amyotrophic lateral sclerosis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence TIGLUTIK dominance.
• Other emerging products for Amyotrophic Lateral Sclerosis are expected to give tough market competition to TIGLUTIK and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of TIGLUTIK in Amyotrophic Lateral Sclerosis.
• Our in-depth analysis of the forecasted sales data of TIGLUTIK from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the TIGLUTIK in Amyotrophic Lateral Sclerosis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of TIGLUTIK?
• What is the clinical trial status of the study related to TIGLUTIK in Amyotrophic lateral sclerosis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the TIGLUTIK development?
• What are the key designations that have been granted to TIGLUTIK for Amyotrophic Lateral Sclerosis?
• What is the forecasted market scenario of TIGLUTIK for Amyotrophic Lateral Sclerosis?
• What are the forecasted sales of TIGLUTIK in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available in Amyotrophic Lateral Sclerosis and how are they giving competition to TIGLUTIK for Amyotrophic Lateral Sclerosis?
• Which are the late-stage emerging therapies under development for the treatment of Amyotrophic Lateral Sclerosis?